SQUIRE PATTON BOGGS for GENENTECH, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. Legislation related to altering sequestration targets. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax "extenders"). Corporate tax reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN O'NEILL | — |
| MANNY ROSSMAN | Staff,Crane,01-04;Staff,Lott,05-06;Ofce,Whip,07-09 |
Medical/Disease Research/Clinical Labs MED
Implementation of healthcare reform law. FDA drug approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PDUFA reauthorization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN O'NEILL | — |
| MANNY ROSSMAN | Staff,Crane,01-04;Staff,Lott,05-06;Ofce,Whip,07-09 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.